Table 3.
Meta-analysis of PLMS+ combined cohorts compared with restless leg syndrome (RLS) (Didriksen et al. [22])
| Marker information (Didricksen) | RLS (Didriksen et al. [22]) | PLMS+ (this study) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| rsName | Band | EAF Europe | EA | OA | Closest gene | P-value | Odds ratio (95% CI) | P-value | Odds ratio (95% CI) |
| rs10177089 | 2p25.3 | 0.38882 | C | T | 8.49e−12 | 0.89 (0.86–0.93) | 2.10E–04 | 0.92 (0.88–0.97) | |
| rs3784709 | 15q23 | 0.30409 | T | C | MAP2K5 | 4.91e−28 | 0.82 (0.79–0.86) | 7.16E−03 | 0.95 (0.91–0.99) |
| rs4714163 | 6p21.2 | 0.29530 | C | T | BTBD9 | 3.11e−50 | 0.76 (0.73–0.8) | 3.70E−10 | 0.83 (0.77–0.89) |
| rs7034030 | 9p24.1 | 0.16055 | G | C | PTPRD | 1.47e−11 | 1.15 (1.11–1.19) | 1.94E−03 | 1.08 (1.03–1.14) |
| rs10208712 | 2p25.3 | 0.35111 | G | A | 2.34e−09 | 0.91 (0.88–0.94) | 2.35E−04 | 0.92 (0.88–0.97) | |
| rs10952927 | 7q21.13 | 0.13149 | G | A | 1.9e−09 | 1.13 (1.09–1.17) | 1.12E−03 | 1.08 (1.04–1.13) | |
| rs111652004 | 15q21.1 | 0.10322 | T | G | 2.2e−11 | 0.83 (0.77–0.88) | 1.59E−04 | 0.88 (0.82–0.95) | |
| rs113851554 | 2p14 | 0.05670 | T | G | MEIS1 | 4.5e−100 | 1.89 (1.83–1.94) | 3.51E−12 | 1.63 (1.49–1.76) |
| rs12046503 | 1p21.1 | 0.41907 | C | T | 1.09e−17 | 1.15 (1.11–1.18) | 2.97E−03 | 1.06 (1.02–1.1) | |
| rs12450895 | 17q21.32 | 0.20817 | A | G | 5.69e−06 | 1.09 (1.05–1.13) | 1.28E−03 | 1.08 (1.03–1.12) | |
| rs12962305 | 18q12.3 | 0.25833 | T | C | 0.0113 | 1.03 (1.01–1.05) | 7.90E−01 | 1.01 (0.96–1.05) | |
| rs17636328 | 6p21.2 | 0.17932 | G | A | 7.63e−08 | 0.90 (0.86–0.94) | 3.63E−02 | 0.95 (0.9–1) | |
| rs1820989 | 2p14 | 0.45302 | A | C | 2.86e−13 | 0.90 (0.87–0.93) | 5.33E−02 | 1.06 (1–1.12) | |
| rs1836229 | 9p24.1 | 0.48598 | G | A | PTPRD | 3.68e−08 | 0.92 (0.89–0.95) | 8.40E−03 | 0.95 (0.91–0.99) |
| rs1848460 | 3p26.2 | 0.24450 | T | A | 7.3e−05 | 0.92 (0.87–0.96) | 1.56E−01 | 0.97 (0.93–1.01) | |
| rs340561 | 13q21.33 | 0.18514 | T | G | 0.001 | 1.07 (1.03–1.1) | 1.01E−03 | 1.08 (1.03–1.13) | |
| rs35987657 | 3q22.1 | 0.33340 | G | A | 1.45e−09 | 0.9 (0.87–0.94) | 1.88E−03 | 0.94 (0.9–0.98) | |
| rs365032 | 20q13.33 | 0.26694 | G | A | MYT1 | 2.13e−06 | 1.09 (1.05–1.12) | 3.98E−05 | 1.09 (1.05–1.14) |
| rs45544231 | 16q12.1 | 0.42204 | G | C | 5.71e−34 | 0.82 (0.79–0.85) | 9.38E−05 | 0.93 (0.89–0.97) | |
| rs61192259 | 6p21.2 | 0.40881 | C | A | BTBD9 | 4.71e−30 | 0.83 (0.8–0.86) | 1.87E−07 | 0.89 (0.85–0.93) |
| rs62535767 | 9p23 | 0.32098 | T | C | PTPRD | 2.2e−05 | 0.93 (0.89–0.96) | 1.40E−01 | 0.97 (0.93–1.01) |
| rs80319144 | 2q24.1 | 0.24907 | T | C | CCDC148 | 2.11e−07 | 0.91 (0.87–0.95) | 6.60E−02 | 0.96 (0.91–1) |
| rs868036 | 15q23 | 0.31107 | T | A | MAP2K5 | 4.67e−28 | 0.83 (0.79–0.86) | 1.24E−03 | 0.94 (0.9–0.98) |
| rs996064 | 15q14 | 0.06880 | T | A | 2.8e−08 | 1.21 (1.14–1.27) | 3.01E−04 | 1.2 (1.1–1.31) | |
| rs10068599 | 5q35.1 | 0.32681 | T | C | RANBP17 | 4.29e−08 | 1.10 (1.06–1.13) | 5.66E−01 | 1.01 (0.97–1.05) |
| rs10188680 | 2q32.2 | 0.41022 | T | A | SLC40A1 | 4.28e−08 | 1.09 (1.06–1.13) | 4.85E−01 | 1.01 (0.98–1.05) |
| rs10769894 | 11p15.4 | 0.44845 | A | G | 6.62e−10 | 0.90 (0.87–0.93) | 5.18E−02 | 0.96 (0.92–1) | |
| rs112716420 | 7p22.3 | 0.07505 | G | C | 4.49e−14 | 1.25 (1.19–1.31) | 2.62E−02 | 1.09 (1.01–1.16) | |
| rs58127855 | 18q21.32 | 0.0053 | T | C | 5.06e−09 | 4.72 (4.2–5.24) | 7.21E−01 | 0.97 (0.83–1.12) | |
| rs112716420 | 7p22.3 | 0.07505 | G | C | MICALL2 | 1.5e−18 | 1.25 (1.19–1.31) | 2.62E−02 | 1.09 (1.01–1.16) |
| rs10769894 | 11p15.4 | 0.44845 | A | G | LMO1 | 9.4e−14 | 0.90 (0.88–0.93) | 5.18E−02 | 0.96 (0.92–1) |
| rs10068599 | 5q35.1 | 0.32681 | T | C | RANBP17 | 6.9e−10 | 1.09 (1.06–1.12) | 5.66E−01 | 1.01 (0.97–1.05) |
| rs10188680 | 2q32.2 | 0.41022 | T | A | SLC40A1 | 5.4e−08 | 1.07 (1.05–1.11) | 4.85E−01 | 1.01 (0.98–1.05) |
| rs58127855 | 18q21.32 | 0.0053 | T | C | PMAIP1 | 6.3e−07 | 3.03 (2.01–4.97) | 7.21E−01 | 0.97 (0.83–1.12) |
Note: rsName, reference SNP ID; EAF, effect allele frequency in European ancestry; EA, effect allele; OA, other allele. Odds ratios are presented with 95% confidence intervals in parentheses. Statistics for restless leg syndrome were obtained from Didriksen et al. [22].